Patients rebleeding in the key study populations of repeated hepatic venous pressure gradient (HVPG) measurement in the pharmacological prevention of variceal rebleeding (absolute numbers in parentheses)
| Feu15 | Villanueva16 | McCormick17 | Villanueva4 | Patch6 | |
|---|---|---|---|---|---|
| *Initial cohort 121 patients, 86 of whom were included (43 for each treatment arm). | |||||
| †Initial cohort 233 patients, 144 of whom were included (72 for each treatment arm). | |||||
| ‡Initial cohort 205 patients, 102 of whom were included (51 for each treatment arm). | |||||
| §Only 44 patients included in the study (one patient excluded because of low initial and repeat HVPG (7 mm Hg)). | |||||
| ¶Rebleeding rate in both non-measured and non-remeasured patients (rebleeding occurred in two of seven patients who did not have their baseline HVPG measured and in three of 11 patients who did not have a repeat HVPG measurement). | |||||
| **Number not stated (in the second study (Villanueva4) it can be derived that this number must be between 1 and 4). | |||||
| Total No of patients | 83 | 43* | 63 | 72† | 51‡ |
| HVPG not measured | 17%(14) | 0% | 11%(7) | 0% | 22%(11) |
| HVPG not remeasured | 17%(14) | 28%(12) | 17%(11)§ | 33%(23) | 65%(33) |
| Rebleeding not remeasured | 64%(9/14) | 17%(2/12) | 28%(5/18)¶ | 17%(4/23) | 33%(11/33) |
| Rebleeding (patient groups) | |||||
| Total | 36%(25/69) | 26%(11/43) | 37%(16/44) | 33%(24/72) | 37%(19/51) |
| Haemodynamic responders | 8%(2/25) | 7%(1/14) | 43%(12/28) | 16%(4/25) | 11%(1/9) |
| Haemodynamic non-responders | 52%(23/44) | 47%(8/17) | 25%(4/16) | 67%(16/24) | 22%(2/9) |
| Repeat HVPG ⩽12 mm Hg | 0%(0/8) | 0%(0/9) | 30%(7/23) | ?(?/7) | 50%(1/2) |
| Rebleeding before remeasurement | 7%(5/69) | Some** | 16%(7/44) | Some** | 22%(5/23) |